NovaBridge Biosciences (NBP) Balance Sheet
As of 2025-12-31 (20-F), NovaBridge Biosciences (NBP) reported total assets of $260.5M, total liabilities of $29.6M and shareholders' equity of $230.9M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $210.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NBPNovaBridge BiosciencesFollow NBP — free
—
Price chart with a free account
- Market cap
- 365.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Apr, in 163 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Dec 25 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 163.4 | 729.3 | 552.9 | 342.9 | 291.5 | 68.3 | 210.6 | 210.6 | |
| Short-term investments | 4.6 | 4.8 | 118.2 | 34.1 | 20.2 | 105.1 | 0.2 | 0.2 | |
| Receivables | — | 20.0 | 5.2 | 0.0 | — | — | — | — | |
| Inventory | — | — | 4.3 | 0.0 | — | — | — | — | |
| Current assets | 195.5 | 819.0 | 750.4 | 525.8 | 329.9 | 176.7 | 217.5 | 217.5 | |
| Total assets | 249.6 | 970.7 | 878.9 | 590.6 | 368.9 | 212.7 | 260.5 | 260.5 | |
| Current liabilities | 84.5 | 88.3 | 97.9 | 109.9 | 58.1 | 8.5 | 26.9 | 26.9 | |
| Short-term debt | 7.2 | — | — | 2.7 | 4.2 | — | — | — | |
| Total liabilities | 96.0 | 108.3 | 163.5 | 168.7 | 126.3 | 11.5 | 29.6 | 29.6 | |
| Shareholders' equity | -292.3 | 862.4 | 715.1 | 417.8 | 242.6 | 201.2 | 230.9 | 230.9 |
USD millions · SEC XBRL
NovaBridge Biosciences — questions
- How much cash does NovaBridge Biosciences have?
- $210.6M in cash and cash equivalents as of 2025-12-31.
- What are NovaBridge Biosciences's total assets?
- $260.5M as of 2025-12-31.
- What is NovaBridge Biosciences's shareholders' equity?
- $230.9M as of 2025-12-31.
Every figure on this page comes from NovaBridge Biosciences's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.